Answers are grounded in this paper and cite their sources.
Cannabinoid biosynthesis in Cannabis sativa is governed by a specialized metabolic pathway that culminates in the production of a diverse set of bioactive compounds. The first committed step in this pathway is the synthesis of cannabigerolic acid, which serves as a common precursor to other cannabinoids. This step is followed by the enzymatic conversion of cannabigerolic acid into tetrahydrocannabinolic acid, cannabidiolic acid, and other cannabinoids by a family of cannabinoid oxidocyclase enzymes. Disruption of these enzymes can lead to the accumulation of cannabigerolic acid, resulting in a cannabigerol-dominant cannabinoid profile. Previous research has identified several independent mutations that, when homozygous, result in this cannabigerol-dominant cannabinoid profile. In this study, we characterized the architecture of the haplotypes surrounding four of these mutations, including a structural variant with a complete deletion of cannabidiolic acid synthase. Additionally, we compared these haplotypes to homologous regions from more than 150 publicly available genome assemblies to put them in the context of global variation at this important and structurally variable genomic region identifying 39 structurally-distinct haplogroups. We developed high-throughput molecular markers to assay for each of the mutated haplogroups. Further, we generated and characterized more than 30 populations complementing these mutated haplogroups with each other, and with fully functional haplogroups, to characterize haplogroup-associated variation in cannabinoid profiles. Together, our findings provide insights into the genetic basis of cannabinoid diversity and offer molecular tools for manipulating cannabinoid profiles in C. sativa.
No takes yet. Share an insight, caveat, or question.
Stack et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: